1334P Efficacy and safety of anlotinib plus docetaxel in non-small cell lung cancer (NSCLC) after failure of previous immune checkpoint inhibitors (ICIs) therapy: Results from a phase I/II trial

Autor:	Hongming Pan, D. Zhu, F. Lan, L. Lu, X. Yang, Yong Fang, Chuang-Zhou Rao, Jiawei Shou, W. Hong, Yongyan Wang, Q. Guo, Jun Chen
Rok vydání:	2021
Předmět:	Phase i ii Oncology Docetaxel business.industry Immune checkpoint inhibitors medicine Cancer research non-small cell lung cancer (NSCLC) Hematology medicine.disease business medicine.drug
Zdroj:	Annals of Oncology. 32:S1021
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.1935
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7cd105519da1821ba9c1d9f0a66cec4c https://doi.org/10.1016/j.annonc.2021.08.1935 Zobrazit plný text záznamu